ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year... (ss Platform (AXP(TM)) is a proprietary f...)

ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year

Date:2/6/2008

ss Platform (AXP(TM)) is a proprietary family of

automated devices that includes the AXP and the MarrowXpress(TM) and

companion sterile blood processing disposable for harvesting stem

cells in a closed system. The AXP device is used for the processing

of cord blood. GE Healthcare is the exclusive global distribution

partner for the AXP cord blood product. The MarrowXpress is used

for isolating stem cells from bone marrow. ThermoGenesis sells the

MarrowXpress directly to global customers.

-- The CryoSeal(R) FS System, an automated device and companion sterile

blood processing disposable, is used to prepare fibrin sealants from

plasma in about an hour. We received FDA approval to market the

CryoSeal FS System in liver resection surgeries in July 2007. The

CryoSeal FS System has received the CE-Mark. From a marketing

perspective, the CE Mark is the European equivalent to an FDA

approval, in that it allows sales of the product throughout the

European community. Asahi Medical is the exclusive distributor for

the CryoSeal System in Japan and the Company markets through

independent distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood

processing disposable that prepares activated thrombin from a small

aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

currently being marketed in Europe by Biomet, Inc., subsidiary

Biomet Biologics, Medtronic, Inc. and independent distributors.

THERMOGENESIS CORP.

Condensed Balance Sheets

(Unaudited)

December 31, 2007 June 30, 2007

ASSETS

Current assets:

'/>"/>

Post Your Comments:

ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year...(ss Platform (AXP(TM)) is a proprietary f...)